PARP1 and breast carcinoma: The treatment with PARP inhibitors boosted PD-L1 expression in breast cancer cells, decreasing the number of tumor-infiltrating cytotoxic T cells in a xenograft model, whereas the combination of PARP inhibitors and anti-PD-L1 antibody reversed the immunosuppressant effect [154].